EligoChem Limited

Life Sciences
Drug design
Aim of funding: 
HMRC Advance Assurance received: 

EligoChem Limited


EligoChem has developed a proprietary and patentable technology that facilitates the design of highly water-soluble drugs that are absorbed well by the human body.  One in fifteen known drug compounds have this combination of properties, but they are present in only one in ten thousand compounds in current pharma screening collections. This technology is particularly suited to antibiotic drug discovery.

Since its founding, the Company’s technology has created a library of diverse drug-like compounds that possess this water-soluble property, and has achieved proof of concept for the technology through demonstration of high absorption, increased safety profile (6x lower incidence of toxic effects than average) and the identification of novel anti-biotic solutions to MRSA and Tuberculosis.

The Company has also forged collaborations with leading University research groups in the antibiotic field and has applied DNA-coded screening of millions of compounds, aligned with the Eligochem design technology, to identify novel antibiotic compound series. 


EligoChem’s technology facilitates the ability to design and select compounds which, although polar, are well absorbed by human cells and thus are potentially suited to the discovery and optimisation of novel antibiotics.

In the medium term, 12-18 months, the Company will seek to screen compound libraries, with the intention to progress any pharma indications into leads.

Over the longer term, 18 months-5 years, the Company intends to progress leads into drug candidates.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.